More than 99 percent of cervical cancers are caused by persistent high-risk HPV infection 1 Cervical cancer is nearly 100 percent preventable with proper HPV vaccination, screening and treatment; ...

The Food and Drug Administration approved the Roche cobas HPV Test to detect human papilloma virus through the use of cervical cells collected for a Pap test and stored in SurePath Preservative Fluid.

Basel, 16 June 2022 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced the launch of a human papillomavirus (HPV) self sampling solution in countries accepting the CE mark. This new solution enables ...

The U.S. Food and Drug Administration’s Medical Devices Advisory Committee Microbiology Panel unanimously voted that Roche Molecular Systems’ cobas viral DNA test is safe and effective as a ...

Roche Diagnostics is looking to a new screening tool to help women learn in a more private way if they are at increased risk for cervical cancer—a self-collection test to identify HPV. With the test, ...

Survey findings from over 8,700 people in 12 countries show that half of those polled have inadequate understanding of HPV, with nearly one-third being unsure or unaware of it altogether.1 Findings ...

The FDA has approved an alternative to the traditional Pap smear. The U.S. Food and Drug Administration has approved a genetic test from Swiss drug maker Roche as the first U.S.-approved alternative ...

Let's be honest: Pap smears are terrible. Every year, I stare at the ceiling and try my hardest to ignore the scraping of my insides. In the age of AI chatbots and self-driving cars, how has no one ...

Please provide your email address to receive an email when new articles are posted on . The FDA approved expanded indications for the self-collection of vaginal swabs for HPV tests. The approval will ...

Editor's Note: One hundred years ago, Dr. George Papanicolaou first put vaginal smears under the microscope to study human vaginal cytology, using samples supplied by his wife. [1] Dr. Papanicolaou ...

New research commissioned by Switzerland-based Roche found that almost a third of millennial women—those ages 29-42—miss their cervical screening appointments. The survey released this month queried 5 ...

However, more than 70% of the respondents indicated they would be interested in the option of collecting their own sample for screening if available. The research also demonstrated that with screening ...